As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of BioXcel Therapeutics, Inc. The largest reported stake is Integrated Core Strategies (US) LLC's, at 8.4%. 5 filings are on record since October 1, 2025 (Schedule 13G/A, February 9, 2026).
Sell to companies like BioXcel Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Armistice Capital, LLC · Sole voting: 0 · Shared voting: 1,621,716 · Sole dispositive: 0 · Shared dispositive: 1,621,716 · SCHEDULE 13G/A, 2026-08-14
- · Holder: Armistice Capital, LLC · Percent: 7.05% · SCHEDULE 13G
- · Reporting person: Qatar Investment Authority · Sole voting: 156,066 · Shared voting: 0 · Sole dispositive: 156,066 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-03-30
- · Reporting person: Integrated Core Strategies (US) LLC · Sole voting: 0 · Shared voting: 1,833,717 · Sole dispositive: 0 · Shared dispositive: 1,833,717 · SCHEDULE 13G/A, 2026-02-09
- · Holder: Integrated Core Strategies (US) LLC · Percent: 5.2% · SCHEDULE 13G
BioXcel Therapeutics, Inc. has 5 Schedule 13D or 13G filings on record since 2025-10-01. 1 holder's latest filing reports 5% or more of common stock, par value $0.001. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Integrated Core Strategies (US) LLC | 8.4% | 1,833,717 | SCHEDULE 13G/A, 2026-02-09 | 2025-12-31 |
| Armistice Capital, LLC | 4.99% | 1,621,716 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Qatar Investment Authority | 0.6% | 156,066 | SCHEDULE 13G/A, 2026-03-30 | 2025-12-31 |
Holding shares or following this stake? See who's behind BioXcel Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on BioXcel Therapeutics, Inc. and the records around it.
BioXcel Therapeutics, Inc. elsewhere on the record
Companies that share a holder
- Qatar Investment Authority also filed stake reports on 11 other companies: Aspen Neuroscience, Inc. (Nov 2026), Global Business Travel Group, Inc. (Sep 2026), Nanobiotix SA (Jul 2026)
- Integrated Core Strategies (US) LLC also filed stake reports on 63 other companies: SkinHealth Systems Inc. (Nov 2026), Infinite Eagle Acquisition Corp. (Nov 2026), Longeveron Inc. (Nov 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), Bluejay Diagnostics (Aug 2026)
Watch BioXcel Therapeutics, Inc.
Get an email when BioXcel Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on BioXcel Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on BioXcel Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on BioXcel Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Integrated Core Strategies (US) LLC | 0 | 1,833,717 | 0 | 1,833,717 | SCHEDULE 13G/A, 2026-02-09 |
| Millennium Management LLC | 0 | 1,835,192 | 0 | 1,835,192 | SCHEDULE 13G/A, 2026-02-09 |
| Millennium Group Management LLC | 0 | 1,835,192 | 0 | 1,835,192 | SCHEDULE 13G/A, 2026-02-09 |
| Israel A. Englander | 0 | 1,835,192 | 0 | 1,835,192 | SCHEDULE 13G/A, 2026-02-09 |
| Armistice Capital, LLC | 0 | 1,621,716 | 0 | 1,621,716 | SCHEDULE 13G/A, 2026-08-14 |
| Steven Boyd | 0 | 1,621,716 | 0 | 1,621,716 | SCHEDULE 13G/A, 2026-08-14 |
| Qatar Investment Authority | 156,066 | 0 | 156,066 | 0 | SCHEDULE 13G/A, 2026-03-30 |
The latest filing identifies BioXcel Therapeutics, Inc. by CUSIP 09075P204 and gives its principal executive office as 555 Long Wharf Drive, New Haven, CT 06511 (SCHEDULE 13G/A, 2026-08-14).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-10-01 | Integrated Core Strategies (US) LLC | 5.2% | SCHEDULE 13G |
| 2026-02-09 | Integrated Core Strategies (US) LLC | 8.4% | SCHEDULE 13G/A |
| 2026-03-30 | Qatar Investment Authority | 0.6% | SCHEDULE 13G/A |
| 2026-05-15 | Armistice Capital, LLC | 7.05% | SCHEDULE 13G |
| 2026-08-14 | Armistice Capital, LLC | 4.99% | SCHEDULE 13G/A |
Questions about who owns BioXcel Therapeutics, Inc.
Who owns BioXcel Therapeutics, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of BioXcel Therapeutics, Inc.: Integrated Core Strategies (US) LLC (8.4%, Schedule 13G/A, filed 2026-02-09).
When did Integrated Core Strategies (US) LLC buy into BioXcel Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Integrated Core Strategies (US) LLC on this page is the Schedule 13G, filed 2025-10-01, reporting 5.2%; its latest, Schedule 13G/A filed 2026-02-09, reports 8.4%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for BioXcel Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 30, 2026 | Leadership change: Samir Saleem appointed, President, and 1 more | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for BioXcel Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.